Floatz logo

Futibatinib

Esophageal Adenocarcinoma

Taiho Oncology, Inc.Small moleculePhase 2Active
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
73/ 100

Competitive context

47 Active assets in the Esophageal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
I-Mab Biopharma US Limited
Phase 3BB
Cetuximab
BeOne Medicines
Phase 2B
Capecitabine
I-Mab Biopharma US Limited
Phase 3B
Tislelizumab
BeOne Medicines
Phase 3B
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3B

View all 50 →

Same molecule, other indications

Futibatinib is also rated in:

Advanced or Metastatic Solid TumorDormant
CCC
Indicative ·
54 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →